Antisense oligodeoxynucleotide for micro RNA-155 seed sequence and application

Abstract

The invention discloses an antisense oligodeoxynucleotide for a micro RNA-155 seed sequence and an application. Micro antisense nucleic acids t-antimiR-155 of eight basic groups are designed and synthesized for the miR-155 seed sequence. T-antimiR-155 transfection cell test shows that t-antimiR-155 is targeted to miRNA-155 of a RPMI-8266 cell strain, so that cell growth is remarkably inhibited and apoptosis is remarkably increased. The test shows that t-antimiR-155 can effectively inhibit growth of lymphoma cells by interfering expression of the miRNA-155, and meanwhile, the test shows that the miRNA-155 can probably be taken as a potential target spot for gene therapy of lymphoma. The t-antimiR-155 can be used for preparing anti-tumor medicines, and particularly medicines for treating multiple myeloma.

Description

technical field

[0001] The invention belongs to the field of molecular biology, and in particular relates to an antisense oligonucleotide (tiny anti-mR-155, t-antimiR-155) targeting microRNA-155 (microRNA, miRNA) seed sequence and its application. Background technique

[0002] Multiple myeloma (MM) is a malignant plasma cell clonal proliferative disease, and its pathogenesis involves multiple aspects, including abnormal chromosome number, translocation, gene mutation, epigenetic changes and changes in the bone marrow microenvironment . The onset of multiple myeloma presents a multi-step process. Early chromosomal translocations involve chromosome 14 (14q32.33) and chromosome 4 (4p16.3), resulting in adjacent MMSET (multiple myeloma SET) on chromosome 4. protein) gene and fibroblast growth factor receptor 3 (fibroblast growth factor receptors, FGFR3) gene were separated. As the disease progresses, recurrent chromosomal translocations, mutations in related genes (involving a...

Images